Your browser doesn't support javascript.
loading
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Hoes, Louisa R; van Berge Henegouwen, Jade M; van der Wijngaart, Hanneke; Zeverijn, Laurien J; van der Velden, Daphne L; van de Haar, Joris; Roepman, Paul; de Leng, Wendy J; Jansen, Anne M L; van Werkhoven, Erik; van der Noort, Vincent; Huitema, Alwin D R; Gort, Eelke H; de Groot, Jan Willem B; Kerver, Emile D; de Groot, Derk Jan; Erdkamp, Frans; Beerepoot, Laurens V; Hendriks, Mathijs P; Smit, Egbert F; van der Graaf, Winette T A; van Herpen, Carla M L; Labots, Mariette; Hoeben, Ann; Morreau, Hans; Lolkema, Martijn P; Cuppen, Edwin; Gelderblom, Hans; Verheul, Henk M W; Voest, Emile E.
Afiliação
  • Hoes LR; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.
  • van Berge Henegouwen JM; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van der Wijngaart H; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Zeverijn LJ; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • van der Velden DL; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • van de Haar J; Department of Medical Oncology, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Roepman P; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.
  • de Leng WJ; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Jansen AML; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.
  • van Werkhoven E; Division of Molecular Oncology & Immunology, Netherlands Cancer Institute Amsterdam, the Netherlands.
  • van der Noort V; Oncode Institute, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Huitema ADR; Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Gort EH; Hartwig Medical Foundation, Amsterdam, the Netherlands.
  • de Groot JWB; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Kerver ED; Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • de Groot DJ; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Erdkamp F; Biometrics Department, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Beerepoot LV; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Hendriks MP; Department of Pharmacy & Pharmacology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Smit EF; Department of Pharmacology, Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • van der Graaf WTA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
  • van Herpen CML; Isala Oncology Center, Isala, Zwolle, the Netherlands.
  • Labots M; Department of Medical Oncology, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.
  • Hoeben A; Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands.
  • Morreau H; Department of Medical Oncology, Zuyderland Hospital, Sittard-Geleen, the Netherlands.
  • Lolkema MP; Department of Medical Oncology, Elisabeth-Tweesteden Hospital, Tilburg, the Netherlands.
  • Cuppen E; Department of Medical Oncology, Northwest Clinics, the Netherlands.
  • Gelderblom H; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Verheul HMW; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Voest EE; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
Clin Cancer Res ; 28(7): 1402-1411, 2022 04 01.
Article em En | MEDLINE | ID: mdl-35046062
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas B-raf / Neoplasias Tipo de estudo: Guideline / Prognostic_studies Limite: Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2022 Tipo de documento: Article